Monopar Therapeutics (MNPR) Cash & Current Investments: 2016-2020
Historic Cash & Current Investments for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $18.0 million.
- Monopar Therapeutics' Cash & Current Investments rose 300.10% to $18.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $56.3 million, marking a year-over-year increase of 151.52%. This contributed to the annual value of $13.2 million for FY2019, which is 91.71% up from last year.
- Per Monopar Therapeutics' latest filing, its Cash & Current Investments stood at $18.0 million for Q3 2020, which was up 43.33% from $12.5 million recorded in Q2 2020.
- Over the past 5 years, Monopar Therapeutics' Cash & Current Investments peaked at $18.0 million during Q3 2020, and registered a low of $2.9 million during Q4 2016.
- For the 3-year period, Monopar Therapeutics' Cash & Current Investments averaged around $9.4 million, with its median value being $8.2 million (2018).
- In the last 5 years, Monopar Therapeutics' Cash & Current Investments slumped by 41.00% in 2019 and then skyrocketed by 300.10% in 2020.
- Quarterly analysis of 5 years shows Monopar Therapeutics' Cash & Current Investments stood at $2.9 million in 2016, then soared by 240.48% to $9.8 million in 2017, then decreased by 29.54% to $6.9 million in 2018, then soared by 91.71% to $13.2 million in 2019, then spiked by 300.10% to $18.0 million in 2020.
- Its Cash & Current Investments was $18.0 million in Q3 2020, compared to $12.5 million in Q2 2020 and $12.6 million in Q1 2020.